The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies

Blood Cancer Journal

Volumn 5, Issue 4, 2015, Pages

  Dosani, T ^a   Carlsten, M ^b   Maric, I ^c   Landgren, O ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW CELL; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; MULTIPLE MYELOMA; NATURAL KILLER CELL; PATHOLOGY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TRANSPLANTATION;

BONE MARROW CELLS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MULTIPLE MYELOMA; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 84961551887     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/BCJ.2015.32     Document Type: Review

References (100)

1. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412–5417.
2. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418–5422.
3. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 2011; 117: 5573–5581.
4. Kristinsson SY, Goldin LR, Bjorkholm M, Koshiol J, Turesson I, Landgren O. Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica 2009; 94: 1581–1589.
5. Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586–2592.
6. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111: 785–789.
7. Feyler S, Selby PJ, Cook G. Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM). Blood Rev 2013; 27: 155–164.
8. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138: 563–579.
9. Balakumaran A, Robey PG, Fedarko N, Landgren O. Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Rev Mol Diagn 2010; 10: 465–480.
10. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9: 503–510.
11. Frohn C, Hoppner M, Schlenke P, Kirchner H, Koritke P, Luhm J. Anti-myeloma activity of natural killer lymphocytes. Br J Haematol 2002; 119: 660–664.
12. Godfrey J, Benson DM Jr. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma 2012; 53: 1666–1676.
13. Osterborg A, Nilsson B, Bjorkholm M, Holm G, Mellstedt H. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol 1990; 45: 153–157.
14. Garcia-Sanz R, Gonzalez M, Orfao A, Moro MJ, Hernandez JM, Borrego D et al. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol 1996; 93: 81–88.
15. Famularo G, D'Ambrosio A, Quintieri F, Di Giovanni S, Parzanese I, Pizzuto F et al. Natural killer cell frequency and function in patients with monoclonal gammopathies. J Clin Lab Immunol 1992; 37: 99–109.
16. Gonzalez M, San Miguel JF, Gascon A, Moro MJ, Hernandez JM, Ortega F et al. Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol 1992; 39: 84–89.
17. Van den Hove LE, Meeus P, Derom A, Demuynck H, Verhoef GE, Vandenberghe P et al. Lymphocyte profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: flow-cytometric characterization and analysis in a two-dimensional correlation biplot. Ann Hematol 1998; 76: 249–256.
18. Buchi G, Girotto M, Termine G, Gario S, Grosso E, Autino R et al. B and T lymphocytic populations and subpopulations and natural killer cells (NK) in blood of patients with myeloma and with monoclonal gammopathy of undetermined significance (MGUS). Pathologica 1985; 77: 385–393.
19. De Rossi G, De Sanctis G, Bottari V, Tribalto M, Lopez M, Petrucci MT et al. Surface markers and cytotoxic activities of lymphocytes in monoclonal gammopathy of undetermined significance and untreated multiple myeloma. Increased phytohemagglutinin-induced cellular cytotoxicity and inverted helper/suppressor cell ratio are features common to both diseases. Cancer Immunol Immunother 1987; 25: 133–136.
20. King MA, Radicchi-Mastroianni MA. Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry. Cytometry 1996; 26: 121–124.
21. Omede P, Boccadoro M, Gallone G, Frieri R, Battaglio S, Redoglia V et al. Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood 1990; 76: 1375–1379.
22. Nielsen H, Nielsen HJ, Tvede N, Klarlund K, Mansa B, Moesgaard F et al. Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors. APMIS 1991; 99: 340–346.
23. Ogmundsdottir HM. Natural killer cell activity in patients with multiple myeloma. Cancer Detect Prev 1988; 12: 133–143.
24. Schutt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Muller S et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006; 47: 1570–1582.
25. Tienhaara A, Pelliniemi TT. Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Lab Haematol 1994; 16: 213–223.
26. Pessoa de Magalhaes RJ, Vidriales MB, Paiva B, Fernandez-Gimenez C, Garcia-Sanz R, Mateos MV et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 2013; 98: 79–86.
27. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 2010; 116: 3865–3874.
28. Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother 2011, 1007 60: 61–73.
29. Fauriat C, Mallet F, Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 2006; 20: 732–733.
30. Jurisic V, Srdic T, Konjevic G, Markovic O, Colovic M. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol 2007; 24: 312–317.
31. Costello RT, Boehrer A, Sanchez C, Mercier D, Baier C, Le Treut T et al. Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy. Immunology 2013; 139: 338–341.
32. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 2007; 67: 8444–8449.
33. Perez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nunez G, Galende J et al. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire. Cancer 2006; 106: 1296–1305.
34. Scheper W, Grunder C, Straetemans T, Sebestyen Z, Kuball J. Hunting for clinical translation with innate-like immune cells and their receptors. Leukemia 2014; 28: 1181–1190.
35. Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105: 251–258.
36. Swift BE, Williams BA, Kosaka Y, Wang XH, Medin JA, Viswanathan S et al. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica 2012; 97: 1020–1028.
37. Benson DM Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116: 2286–2294.
38. Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S et al. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood 2012; 119: 2074–2082.
39. Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother 2013; 62: 1841–1849.
40. Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012; 120: 552–559.
41. Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res 2008; 14: 6895–6906.
42. Mentlik James A, Cohen AD, Campbell KS. Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol 2013; 4: 00481.
43. Yang J, Chu Y, Yang X, Gao D, Zhu L, Wan L et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1472–1483.
44. Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014; 28: 917–927.
45. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008; 111: 3155–3162.
46. Mellstedt H, Holm G, Pettersson D, Bjorkholm M, Johansson B, Lindemalm C et al. T cells in monoclonal gammopathies. Scand J Haematol 1982; 29: 57–64.
47. Mills KH, Cawley JC. Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br J Haematol 1983; 53: 271–275.
48. San Miguel JF, Gonzalez M, Gascon A, Moro MJ, Hernandez JM, Ortega F et al. Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1992; 80: 305–309.
49. Raitakari M, Brown RD, Sze D, Yuen E, Barrow L, Nelson M et al. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br J Haematol 2000; 110: 203–209.
50. Koike M, Sekigawa I, Okada M, Matsumoto M, Iida N, Hashimoto H et al. Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leuk Res 2002; 26: 705–711.
51. Ogawara H, Handa H, Yamazaki T, Toda T, Yoshida K, Nishimoto N et al. High Th1/Th2 ratio in patients with multiple myeloma. Leuk Res 2005; 29: 135–140.
52. Kay NE, Leong TL, Bone N, Vesole DH, Greipp PR, Van Ness B et al. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood 2001; 98: 23–28.
53. Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010; 116: 3554–3563.
54. Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010; 115: 5385–5392.
55. Dhodapkar KM, Barbuto S, Matthews P, Kukreja A, Mazumder A, Vesole D et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008; 112: 2878–2885.
56. Michalek J, Ocadlikova D, Matejkova E, Foltankova V, Dudova S, Slaby O et al. Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma. Br J Haematol 2010; 148: 859–867.
57. Goodyear O, Piper K, Khan N, Starczynski J, Mahendra P, Pratt G et al. CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 2005; 106: 4217–4224.
58. Brown RD, Yuen E, Nelson M, Gibson J, Joshua D. The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia 1997; 11: 1312–1317.
59. Sze DM, Giesajtis G, Brown RD, Raitakari M, Gibson J, Ho J et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood 2001; 98: 2817–2827.
60. Moss P, Gillespie G, Frodsham P, Bell J, Reyburn H. Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia. Blood 1996; 87: 3297–3306.
61. Halapi E, Werner A, Wahlstrom J, Osterborg A, Jeddi-Tehrani M, Yi Q et al. T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden. Eur J Immunol 1997; 27: 2245–2252.
62. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003; 198: 1753–1757.
63. Norde WJ, Hobo W, van der Voort R, Dolstra H. Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood 2012; 120: 728–736.
64. Brown RD, Pope B, Yuen E, Gibson J, Joshua DE. The expression of T cell related costimulatory molecules in multiple myeloma. Leuk Lymphoma 1998; 31: 379–384.
65. Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE et al. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR(-)/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 2010; 72: 540–547.
66. Martin-Ayuso M, Almeida J, Perez-Andres M, Cuello R, Galende J, Gonzalez-Fraile MI et al. Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired. Oncologist 2008; 13: 82–92.
67. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA 2002; 99: 13009–13013.
68. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 2013; 13: 101–117.
69. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012; 12: 239–252.
70. Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, Leleu X et al. Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. PLoS One 2013; 8: e65075.
71. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. JExpMed2003; 197: 1667–1676.
72. Chan AC, Neeson P, Leeansyah E, Tainton K, Quach H, Prince HM et al. NKT cell defects in multiple myeloma and the impact of lenalidomide therapy. Clin Exp Immunol 2013; 175: 49–58.
73. Song W, van der Vliet HJ, Tai YT, Prabhala R, Wang R, Podar K et al. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res 2008; 14: 6955–6962.
74. Spanoudakis E, Hu M, Naresh K, Terpos E, Melo V, Reid A et al. Regulation of multiple myeloma survival and progression by CD1d. Blood 2009; 113: 2498–2507.
75. Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 2013; 121: 423–430.
76. Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010; 10: 467–478.
77. Burjanadze M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C et al. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 2007; 139: 206–216.
78. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10: 155–167.
79. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96: 384–392.
80. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102: 200–206.
81. Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T et al. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009; 37: 956–968.
82. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005; 19: 664–670.
83. Girlanda S, Fortis C, Belloni D, Ferrero E, Ticozzi P, Sciorati C et al. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells costimulates pamidronate-activated gammadelta lymphocytes. Cancer Res 2005; 65: 7502–7508.
84. Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 2008; 105: 1285–1290.
85. Muntasell A, Magri G, Pende D, Angulo A, Lopez-Botet M. Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection. Blood 2010; 115: 5170–5179.
86. von Lilienfeld-Toal M, Nattermann J, Feldmann G, Sievers E, Frank S, Strehl J et al. Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells. Clin Exp Immunol 2006; 144: 528–533.
87. Costantino CM, Baecher-Allan CM, Hafler DA. Human regulatory T cells and autoimmunity. Eur J Immunol 2008; 38: 921–924.
88. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9: 606–612.
89. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006; 107: 3940–3949.
90. Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, Ashcroft AJ et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-) alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 2009; 144: 686–695.
91. Giannopoulos K, Kaminska W, Hus I, Dmoszynska A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer 2012; 106: 546–552.
92. Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One 2012; 7: e47077.
93. Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006; 107: 301–304.
94. Feyler S, Scott GB, Parrish C, Jarmin S, Evans P, Short M et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contactdependent and antigen-presenting cell-independent. PLoS One 2012; 7: e35981.
95. Wang RF. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Hum Immunol 2008; 69: 811–814.
96. Muthu Raja KR, Plasil M, Rihova L, Pelcova J, Adam Z, Hajek R. Flow cytometrybased enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Cytometry B Clin Cytom 2013.
97. Fischer K, Voelkl S, Heymann J, Przybylski GK, Mondal K, Laumer M et al. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8-double-negative regulatory T cells. Blood 2005; 105: 2828–2835.
98. Favaloro J, Brown R, Aklilu E, Yang S, Suen H, Hart D et al. Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leuk Lymphoma 2013; 55: 1090–1098.
99. Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J 2013; 3: e148.
100. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91–101.